

MEDICAL POLICY

MEDICAL POLICY DETAILS	
Medical Policy Title	Extracorporeal Shock Wave Therapy (ESWT) for Musculoskeletal Conditions and Soft Tissue Wounds
Policy Number	2.01.31
Category	Technology Assessment
Effective Date	10/18/01
Committee Approval Date	02/21/02, 02/20/03, 02/19/04, 02/17/05, 12/15/05, 01/18/07, 10/18/07, 09/18/08, 08/20/09, 07/15/10, 06/16/11, 06/21/12, 08/15/13, 07/17/14, 06/18/15, 06/16/16, 06/15/17, 06/21/18, 05/16/19, 03/19/20, 03/18/21, 03/24/22, 03/23/23, 03/21/24
Current Effective Date	03/21/24
Archived Date	N/A
Archive Review Date	N/A
Product Disclaimer	<ul style="list-style-type: none"> • Services are contract dependent; if a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. • If a commercial product (including an Essential Plan or Child Health Plus product), medical policy criteria apply to the benefit. • If a Medicaid product covers a specific service, and there are no New York State Medicaid guidelines (eMedNY) criteria, medical policy criteria apply to the benefit. • If a Medicare product (including Medicare HMO-Dual Special Needs Program (DSNP) product) covers a specific service, and there is no national or local Medicare coverage decision for the service, medical policy criteria apply to the benefit. • If a Medicare HMO-Dual Special Needs Program (DSNP) product DOES NOT cover a specific service, please refer to the Medicaid Product coverage line.

POLICY STATEMENT

- I. Based upon our criteria and assessment of the peer-reviewed literature, extracorporeal shock wave therapy (ESWT) for the treatment of musculoskeletal conditions, including, but not limited to, chronic plantar fasciitis, tendinitis of the shoulder and elbow, and non-union of fractures, has not been medically proven to be effective and, therefore, is considered **investigational**.
- II. Based upon our criteria and assessment of the peer-reviewed literature, ESWT as a treatment for wound-healing has not been medically proven to be effective and, therefore, is considered **investigational**.

Refer to Corporate Medical Policy #11.01.03 Experimental or Investigational Services

DESCRIPTION

ESWT is proposed as a non-surgical treatment option for musculoskeletal conditions, including chronic plantar fasciitis and tendinitis of the shoulder and elbow, as well as for non-union of fractures. The mechanism by which ESWT achieves a therapeutic intervention in orthopedic conditions is not completely understood, but there are several hypotheses. ESWT may disrupt fibrous tissue, allowing for the subsequent promotion of revascularization and healing of tissue. Also, it is believed that the direct and indirect effects of the shock waves may damage cell membranes, so that nociceptors cannot build up a potential to transmit pain signals. Chronic conditions such as tendinitis can be associated with a substantial degree of scarring and calcium deposition. Calcific deposits may restrict motion, encroach on nerves and blood vessels, causing pain and dysfunction. It is thought that the shock waves will break up these deposits, loosen structures, and promote resorption of calcium, thereby decreasing pain and improving function.

Both high-dose and low-dose focused ESWT have been utilized. A high-dose protocol consists of a single treatment of high-energy shock waves (1300mJ/mm²). This painful procedure requires anesthesia. A low-dose protocol consists of

Medical Policy: EXTRACORPOREAL SHOCK WAVE THERAPY (ESWT) FOR MUSCULOSKELETAL CONDITIONS AND SOFT TISSUE WOUNDS

Policy Number: 2.01.31

Page: 2 of 8

multiple treatments, spaced one week to one month apart, in which a lower dose of shock waves is applied. This protocol does not require anesthesia.

Radial ESWT (rESWT) is generated ballistically by accelerating a bullet to hit an applicator, which transforms the kinetic energy into radially expanding shock waves. Other types of ESWT produce focused shock waves that show deeper tissue penetration, with significantly higher energies concentrated to a small focus. rESWT is described as an alternative to focused ESWT and is said to address larger treatment areas, thus providing potential advantages in superficial applications like tendinopathies.

ESWT is being proposed as a new approach to soft tissue wound healing. It is being studied as a treatment for delayed or chronic, non-healing wounds and also as a therapy to accelerate tissue repair in wounds, such as diabetic ulcers and burns. Although the precise mechanism by which ESWT could provide a therapeutic effect is not known, it is thought that ESWT may decrease inflammation and induce neovascularization, allowing for improved perfusion and accelerated epithelialization.

RATIONALE

The OssaTron device (HealthTronics, Inc.) was approved by the United States Food and Drug Administration (FDA) in July 2000 for chronic proximal plantar fasciitis and is also approved for use in the treatment of lateral epicondylitis. Dornier MedTech, Inc. received FDA premarket approval (PMAF) for the Epos Ultra ESWT device on January 15, 2002 for the treatment of plantar fasciitis. Siemens Healthcare's SONOCUR Basic System was approved in July 2002 for treatment of epicondylitis (tennis elbow). Orthometrix, Inc.'s Orbasone Pain Relief System and Medispec Sdn Bhd (Malaysia)'s Orthospec, received FDA PMA in 2005; both are approved to treat plantar fasciitis. The FDA-labeled indication for the OssaTron and Epos Ultra devices specifically describes a high-dose protocol, while the labeled indication for the SONOCUR device describes a low-dose protocol. In May 2007, the Dolorclast from EMS Electro Medical Systems, Nyon, Switzerland, a rESWT, was approved by FDA through the PMA process.

There is insufficient data published in the peer-reviewed literature to draw conclusions about the effectiveness of either focused ESWT or rESWT for treatment of musculoskeletal conditions. Outcomes of trials on clinically relevant measures are inconsistent, and interpretation is complicated by variations in treatment protocols. Published evidence for the use of ESWT to promote healing of fracture non-union consists of several, relatively small, randomized, controlled trials (RCTs) with methodologic limitations, along with reports of case series, and it cannot be concluded from such studies that ESWT results in acceleration of union. Small RCTs have reported a benefit for pain and functional outcomes for tendinopathies, including shoulder and Achilles tendinopathies; however, many trials have been considered to be of poor quality. More high-quality trials are needed, to determine whether ESWT improves net health outcomes.

Likewise, the available evidence in the medical literature evaluating the safety and efficacy of ESWT for wound healing is insufficient to support its use for this indication at the present time. The Sanuwave Health dermaPACE system received FDA clearance on December 28, 2017. This device provides acoustic pressure shockwaves in the treatment of chronic, full-thickness, diabetic foot ulcers with wound areas measuring no larger than 16 cm², which extend through the epidermis, dermis, tendon, or capsule, but without bone exposure. The dermaPACE System is indicated for diabetic patients aged 22 years and older who present with diabetic foot ulcers greater than 30 days in duration and is indicated for use in conjunction with standard diabetic ulcer care. The FDA reviewed clinical data from two multi-center, randomized, double-blind studies with a total of 336 diabetic patients receiving either usual care plus the dermaPACE System shockwave therapy or usual care plus sham shockwave therapy. In the first study, 206 subjects were randomized to either dermaPACE (n=107) or to a sham-controlled group (n=99). At the 24-week endpoint, the rate of wound closure in the dermaPACE cohort was 39.3%, compared to 26.3% in the control group. In the second study, 130 subjects were randomized to dermaPACE (n=65) or to a sham-controlled group (n=65). At the 24-week endpoint, the rate of wound closure in the dermaPACE cohort was 35.4%, compared to 26.2% in the control group.

CODES

- *Eligibility for reimbursement is based upon the benefits set forth in the member's subscriber contract.*

Medical Policy: EXTRACORPOREAL SHOCK WAVE THERAPY (ESWT) FOR MUSCULOSKELETAL CONDITIONS AND SOFT TISSUE WOUNDS

Policy Number: 2.01.31

Page: 3 of 8

- *CODES MAY NOT BE COVERED UNDER ALL CIRCUMSTANCES. PLEASE READ THE POLICY AND GUIDELINES STATEMENTS CAREFULLY.*
- *Codes may not be all inclusive as the AMA and CMS code updates may occur more frequently than policy updates.*
- *Code Key: Experimental/Investigational = (E/I), Not medically necessary/ appropriate = (NMN).*

CPT Codes

Code	Description
0101T (E/I)	Extracorporeal shock wave involving musculoskeletal system, not otherwise specified
0102T (E/I)	Extracorporeal shock wave, high energy, performed by a physician, requiring anesthesia other than local, involving lateral humeral epicondyle
0512T (E/I)	Extracorporeal shock wave for integumentary wound healing, high energy, including topical application and dressing care; initial wound
0513T (E/I)	each additional wound (List separately in addition to code for primary procedure)
28890 (E/I)	Extracorporeal shock wave, high energy, performed by a physician or other qualified health care professional, requiring anesthesia other than local, including ultrasound guidance, involving the plantar fascia

Copyright © 2024 American Medical Association, Chicago, IL

HCPCS Codes

Code	Description
No specific code(s)	

ICD10 Codes

Code	Description
G56.00-G56.03	Carpal tunnel syndrome (code range)
M72.2	Plantar fascial fibromatosis
M75.00-M75.02	Adhesive capsulitis of shoulder (code range)
M75.20-M75.22	Bicipital tendinitis (code range)
M75.30-M75.32	Calcific tendinitis of shoulder (code range)
M77.00-M77.02	Medial epicondylitis (code range)
M77.10-M77.12	Lateral epicondylitis, elbow (code range)
M77.30-M77.32	Calcaneal spur, foot (code range)
M87.051-M87.059	Idiopathic aseptic necrosis of femur (code range)
Multiple ICD10 diagnosis codes for open wounds, burns, and fracture nonunion codes	

REFERENCES

Ahadi T, et al. Prolotherapy vs radial extracorporeal shock wave therapy in the short-term treatment of lateral epicondylitis: a randomized clinical trial. Pain Med 2019 Jan 29. [Epub ahead of print]

Avendaño-Coy J, et al. Extracorporeal shockwave therapy improves pain and function in subjects with knee osteoarthritis: A systematic review and meta-analysis of randomized clinical trials. Int J Surg 2020 Oct;82:64-75.

Babatunde OO, et al. Comparative effectiveness of treatment options for plantar heel pain: a systematic review with network meta-analysis. Br J Sports Med 2019 Feb;53(3):182-194.

Medical Policy: EXTRACORPOREAL SHOCK WAVE THERAPY (ESWT) FOR MUSCULOSKELETAL CONDITIONS AND SOFT TISSUE WOUNDS

Policy Number: 2.01.31

Page: 4 of 8

*Baccaglioni W, et al. The role of the low-intensity extracorporeal shockwave therapy on penile rehabilitation after radical prostatectomy: a randomized clinical trial. J Sex Med 2020 Apr;17(4):688-694.

Brunckhorst O, et al. A systematic review of the long-term efficacy of low-intensity shockwave therapy for vasculogenic erectile dysfunction. Int Urol Nephrol 2019 May;51(5):773-781.

*Buchbinder R, et al. Systematic review of the efficacy and safety of shock wave therapy for lateral elbow pain. J Rheum 2006;33(7):1351-63.

Cabanas-Valdes R, et al. The effectiveness of extracorporeal shock wave therapy to reduce lower limb spasticity in stroke patients: a systematic review and meta-analysis. Top Stroke Rehabil 2020 Mar;27(2):137-157.

*Cacchio A, et al. Extracorporeal shock-wave therapy compared with surgery for hypertrophic long-bone unions. J Bone Joint Surg Am 2009 Nov;91(11):2589-97.

Carlisi E, et al. Focused extracorporeal shock wave therapy for greater trochanteric pain syndrome with gluteal tendinopathy: a randomized controlled trial. Clin Rehabil 2019 Apr;33(4):670-680.

*Chen JM, et al. Functional outcomes of bilateral hip necrosis: total hip arthroplasty versus extracorporeal shockwave. Arch Orthop Trauma Surg 2009 Jun;129(6):837-41.

Chuang YC, et al. Pain reduction realized with extracorporeal shock wave therapy for the treatment of symptoms associated with interstitial cystitis/bladder pain syndrome—A prospective, multicenter, randomized, double-blind, placebo-controlled study. Neurourol Urodyn 2020 Jun;39(5):1505-1514.

*Chuckpaiwong B, et al. Extracorporeal shock wave for chronic proximal plantar fasciitis: 225 patients with results and outcome predictors. J Foot Ankle Surg 2009 Mar-Apr;48(2):148-55.

Cinar E, et al. Extracorporeal shockwave therapy in the management of plantar fasciitis: A randomized controlled trial. Foot (Edinb) 2020 Sep;44:101679.

Di Mauro M, et al. Extracorporeal shock wave therapy in Peyronie's disease: Clinical efficacy and safety from a single-arm observational study. World J Mens Health 2019 Sep;37(3):339-346.

Eftekharsadat B, et al. Comparison of efficacy of corticosteroid injection versus extracorporeal shock wave therapy on inferior trigger points in the quadratus lumborum muscle: a randomized clinical trial. BMC Musculoskelet Disord 2020 Oct 19;21(1):695.

ElGendy MH, et al. Extracorporeal shock wave therapy vs. corticosteroid local injection in shoulder impingement syndrome: a three-arm randomized controlled trial. American Journal of Physical Medicine & Rehabilitation 2023 Jun;102(6): 533-540.

*Furia JP. High-energy extracorporeal shock wave therapy as a treatment for insertional Achilles tendinopathy. A J Sports Med 2006;34(5):733-40.

*Furia JP, et al. Low-energy extracorporeal shock wave therapy as treatment for greater trochanteric pain syndrome. Am J Sports Med 2009 Sep;37(9):1806-13.

*Gerdesmayer L, et al. Radial extracorporeal shock wave therapy is a safe and effective in the treatment of chronic recalcitrant plantar fasciitis: results of a confirmatory randomized placebo-controlled multicenter study. Am J Sports Med 2008 Nov;36(11):2100-9.

Gezginaslan Ö and Başar G. Comparison of effectiveness of density and number of sessions of extracorporeal shock wave therapy in plantar fasciitis patients: A double-blind, randomized-controlled study. J Foot Ankle Surg 2020 Aug 7;S1067-2516(20)30278-7.

*Gollwitzer H, et al. Extracorporeal shock wave therapy for chronic painful heel syndrome: a prospective, double blind, randomized trial assessing the efficacy of a new electromagnetic shock wave device. J Foot Ankle Surg 2007 Sep-Oct;46(5):348-57.

Medical Policy: EXTRACORPOREAL SHOCK WAVE THERAPY (ESWT) FOR MUSCULOSKELETAL CONDITIONS AND SOFT TISSUE WOUNDS

Policy Number: 2.01.31

Page: 5 of 8

- *Greve JM, et al. Comparison of radial shockwaves and conventional physiotherapy for treating plantar fasciitis. Clinics 2009;64(2):97-103.
- *Haake M, et al. Extracorporeal shock wave therapy for plantar fasciitis: randomised controlled multicentre trial. Brit Med J 2003 Jul;327(7406):75-7.
- *Hearnden A, et al. Extracorporeal shock wave therapy in chronic calcific tendinitis of the shoulder- is it effective? Acta Orthop Belg 2009 Feb;75(1):25-31.
- *Ho C. Extracorporeal shock wave treatment for chronic lateral epicondylitis (tennis elbow). Issues Emerg Health Technol 2007 Jan;(96 part 2):1-4.
- Huang Q, et al. Extracorporeal shock wave therapy for treating foot ulcers in adults with type 1 and type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Can J Diabetes 2020 Mar;44(2):196-204.e3.
- *Huisstede BM, et al. Evidence for effectiveness of extracorporeal shockwave therapy (ESWT) to treat calcific and non-calcific rotator cuff tendinosis- a systematic review. Man Ther 2011 Oct;16(5):419-33.
- *Institute for Clinical Systems Improvement. Technology assessment report: extracorporeal shock wave therapy for plantar fasciitis. TA #86. 2004 Nov.
- Jia G, et al. Long-term effects of extracorporeal shock wave therapy on poststroke spasticity: A meta-analysis of randomized controlled trials J Stroke Cerebrovasc Dis 2020 Mar;29(3):104591.
- Joo SY, et al. Clinical utility of extracorporeal shock wave therapy on hypertrophic scars of the hand caused by burn injury: A prospective, randomized, double-blinded study J Clin Med 2020 May 7;9(5):1376.
- Kesikburun S, et al. Comparison of ultrasound-guided prolotherapy versus extracorporeal shock wave therapy in the treatment of chronic plantar fasciitis: A randomized clinical trial. J of Foot and Ankle Surgery 2022; 61: 48-52.
- Kim JC, et al. Effect of extracorporeal shockwave therapy on carpal tunnel syndrome: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore) 2019 Aug;98(33):e16870.
- Kim KS, et al. Electromagnetic low-intensity extracorporeal shock wave therapy in patients with erectile dysfunction: a sham-controlled, double-blind, randomized prospective study. World J Mens Health 2020 Apr;38(2):236-242.
- Knobloch K, et al. Focused electromagnetic high-energetic extracorporeal shockwave (ESWT) reduces pain levels in the nodular state of Dupuytren's disease-a randomized controlled trial (DupuyShock). Lasers Med Sci 2021 Jan 23. [Online ahead of print.]
- Koçak Ulucaköy R, et al. Extracorporeal shock wave therapy as a conservative treatment option for carpal tunnel syndrome: A double-blind, prospective, randomized, placebo-controlled study. Turk J Phys Med Rehabil 2020 Nov 9;66(4):388-397.
- *Kudo P, et al. Randomized, placebo-controlled, double-blind clinical trial evaluating the treatment of plantar fasciitis with an extracorporeal shockwave therapy (ESWT) device; a north American confirmatory study. J Ortho Res 2006 Feb;24(2):115-23.
- Li G, et al. Effects of radial extracorporeal shockwave therapy on spasticity of upper-limb agonist/antagonist muscles in patients affected by stroke: a randomized, single-blind clinical trial. Age Ageing 2020 Feb 27;49(2):246-252.
- Li T, et al. Application and efficacy of extracorporeal shockwave treatment for knee osteoarthritis: A systematic review and meta-analysis. Exp Ther Med 2019 Oct;18(4):2843-2850.
- Li W, et al. Extracorporeal shock wave therapy versus local corticosteroid injection for the treatment of carpal tunnel syndrome: a meta-analysis. J Orthop Surg Res 2020 Nov 23;15(1):556.
- Liao CD et al. Clinical efficacy of extracorporeal shockwave therapy for knee osteoarthritis: a systematic review and meta-regression of randomized controlled trials. Clin Rehabil 2019 Sep;33(9):1419-1430.

Medical Policy: EXTRACORPOREAL SHOCK WAVE THERAPY (ESWT) FOR MUSCULOSKELETAL CONDITIONS AND SOFT TISSUE WOUNDS

Policy Number: 2.01.31

Page: 6 of 8

- Louwerens JK, et al. Comparing ultrasound-guided needling combined with a subacromial corticosteroid injection versus high-energy extracorporeal shockwave therapy for calcific tendinitis of the rotator cuff: A randomized controlled trial. Arthroscopy 2020 Jul;36(7):1823-1833.e1.
- Ma H, et al. The efficacy and safety of extracorporeal shockwave therapy in knee osteoarthritis: A systematic review and meta-analysis. Int J Surg 2020 Jan 21;75:24-34.
- Marotta N, et al. Effect of radial extracorporeal shock wave therapy in reducing pain in patient with temporomandibular disorders: a pilot randomized controlled trial. Applied Sciences 2022 Apr;12(8):3821.
- *Malay DS, et al. Extracorporeal shockwave therapy versus placebo for the treatment of chronic proximal plantar fasciitis: results of a randomized, placebo-controlled, double-blinded, multicenter intervention trial. J Foot Ankle Surg 2006 Jul/Aug;45(4):196-210.
- Mihai EE, et al. Long-term efficacy of extracorporeal shock wave therapy on lower limb post-stroke spasticity: A systematic review and meta-analysis of randomized controlled trials. J Clin Med 2020 Dec 29;10(1):86.
- Mishra BN, et al. Effectiveness of extra-corporeal shock wave therapy (ESWT) vs methylprednisolone injections in plantar fasciitis. J Clin Orthop Trauma 2019 Mar-Apr;10(2):401-405.
- *National Institute for Health and Clinical Excellence. Extracorporeal shockwave therapy for achilles tendinopathy. Interventional procedures guidance [IPG571]. Published: 21 December 2016 [<https://www.nice.org.uk/guidance/ipg571>] accessed 02/01/24.
- *National Institute for Health and Clinical Excellence. Extracorporeal shockwave therapy for refractory plantar fasciitis. Interventional procedures guidance [IPG311]. Published:26 August 2009 [<https://www.nice.org.uk/guidance/ipg311>] accessed 02/01/24.
- *National Institute for Health and Clinical Excellence. Extracorporeal shockwave therapy for refractory tennis elbow. Interventional procedures guidance [IPG313]. Published: 26 August 2009 [<https://www.nice.org.uk/guidance/ipg313>] accessed 02/01/24.
- National Institute for Health and Clinical Excellence. Extracorporeal shockwave therapy for refractory greater trochanter pain syndrome. Interventional procedure [IPG376]. Published: 26 January 2011 [<https://www.nice.org.uk/guidance/ipg376>] accessed 02/01/24.
- *Othman AM, et al. Endoscopic plantar fasciotomy versus extracorporeal shock wave therapy for treatment of chronic plantar fasciitis. Arch Orthop Trauma Surg 2010 Nov;130(11):1343-7.
- *Ottomann C, et al. prospective randomized trial of accelerated re-epithelization of skin graft donor sites using extracorporeal shock wave therapy. J Am Coll Surg 2010 Sep;211(3):361-7.
- *Ozturan KE, et al. Autologous blood and corticosteroid injection and extracorporeal shock wave therapy in the treatment of lateral epicondylitis. Orthopedics 2010 Feb 1;33(2):84-91.
- *Palmier A, et al. A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shockwave therapy for the treatment of Peyronie's disease. Eur Urol 2009 Aug;56(2):363-9.
- Pinitkwamdee S, et al. Effectiveness of extracorporeal shockwave therapy in the treatment of chronic insertional Achilles tendinopathy. Foot Ankle Int 2020 Apr;41(4):403-410.
- *Pleiner J, et al. Extracorporeal shockwave treatment is effective in calcific tendonitis of the shoulder. A randomized controlled trial. Wien Klin Wochenschr 2004;116(15-16):536-41.
- Rai S, et al. Intralesional steroid injection versus extracorporeal shockwave therapy in the treatment of plantar fasciitis: a comparative, prospective, case series study. Cureus 2023 Jan; 15(1): e33593.
- *Rasmussen S, et al. Shockwave therapy for chronic Achilles tendinopathy: a double-blind, randomized clinical trial of efficacy. Acta Orthop 2008 Apr;79(2):249-56.

Medical Policy: EXTRACORPOREAL SHOCK WAVE THERAPY (ESWT) FOR MUSCULOSKELETAL CONDITIONS AND SOFT TISSUE WOUNDS

Policy Number: 2.01.31

Page: 7 of 8

Rhim HC, et al. A systematic review of systematic reviews on the epidemiology, evaluation, and treatment of plantar fasciitis. Life 2021 Nov [Epub ahead of print].

Sagla, G et al. Physical therapy versus radial extracorporeal shock wave therapy in the treatment of carpal tunnel syndrome: a randomized-controlled study. Turk Phys Med Rehab 2022;68(1):126-135.

*Saxena A, et al. Extra-corporeal pulse-activated therapy (“EPAT” sound wave) for Achilles tendinopathy: a prospective study. J Foot Ankle Surg 2011 May-Jun;50(3):315-9.

*Schofer MD, et al. High-versus low-energy extracorporeal shock wave therapy of rotator cuff tendinopathy: a prospective, randomized, controlled study. Acta Orthop Belg 2009 Aug;75(4):452-8.

*Speed CA, et al. Extracorporeal shock wave therapy for plantar fasciitis - A double blind randomised controlled trial. J Orthop Res 2003 Sep;21(5):937-40.

*Staples MP, et al. A randomized controlled trial of extracorporeal shock wave therapy for lateral epicondylitis (tennis elbow). J Rheumatol 2008 Oct;35(10):2038-46.

Stolberg-Stolberg J, et al. Addition of shock wave therapy to nail dynamization increases the chance of long-bone non-union healing. J of Orthopaedics and Traumatology 2022 [Epub ahead of print].

Surace SJ, et al. Shock wave therapy for rotator cuff disease with or without calcification. Cochrane Database Syst Rev 2020 Mar 4;3(3):CD008962.

*Tornese D, et al. Comparison of two extracorporeal shock wave therapy techniques for the treatment of painful subcalcaneal spur. A randomized controlled study. Clin Rehabil 2008 Sep;22(9):780-7.

U.S. Food and Drug Administration (FDA). Device classification Under Section 513 (f)(2)(De Novo). De Novo Classification [https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/denovo.cfm?ID=DEN160037] accessed 02/01/24.

Verze P, et al. Efficacy and safety of low-intensity shockwave therapy plus tadalafil 5 mg once daily in men with type 2 diabetes mellitus and erectile dysfunction: a matched-pair comparison study. Asian J Androl 2019 Nov 1. [Epub ahead of print]

*Vidal X, et al. Radial extracorporeal shock wave therapy (rESWT) in the treatment of spasticity in cerebral palsy: a randomized, placebo-controlled clinical trial. NeuroRehabilitation 2011;29(4):413-9.

Vidal X, et al. Efficacy of radial extracorporeal shock wave therapy compared with botulinum toxin type A injection in treatment of lower extremity spasticity in subjects with cerebral palsy: A randomized, controlled, crossover study. J Rehabil Med 2020 Jun 30;52(6):jrm00076.

Wang TS, et al. Extracorporeal shockwave therapy for chronic knee pain: A multicenter, randomized controlled trial. Altern Ther Health Med 2020 Mar;26(2):34-37.

Wang YC, et al. Efficacy of different energy levels used in focused and radial extracorporeal shockwave therapy in the treatment of plantar fasciitis: A meta-analysis of randomized placebo-controlled trials. J Clin Med 2019 Sep 19;8(9).

Xiong Y, et al. Comparison of efficacy of shock-wave therapy versus corticosteroids in plantar fasciitis: a meta-analysis of randomized controlled trials. Arch Orthop Trauma Surg 2019 Apr;139(4):529-536.

Xu Y, et al. The effect of extracorporeal shock wave therapy on the treatment of moderate to severe knee osteoarthritis and cartilage lesion. Medicine (Baltimore) 2019 May;98(20):e15523.

Yan C, et al. A comparative study of the efficacy of ultrasonics and extracorporeal shock wave in the treatment of tennis elbow: a meta-analysis of randomized controlled trials. J Orthop Surg Res 2019 Aug 6;14(1):248.

Medical Policy: EXTRACORPOREAL SHOCK WAVE THERAPY (ESWT) FOR MUSCULOSKELETAL CONDITIONS AND SOFT TISSUE WOUNDS

Policy Number: 2.01.31

Page: 8 of 8

Zhang J, et al. Comparative efficacy and patient-specific moderating factors of nonsurgical treatment strategies for frozen shoulder: An updated systematic review and network meta-analysis. Am J Sports Med 2020 Sep 17;363546520956293. [Online ahead of print.]

Zhang Q, et al. Efficacy of extracorporeal shockwave therapy on pain and function in myofascial pain syndrome of the trapezius: A systematic review and meta-analysis. Arch Phys Med Rehabil 2020 Aug;101(8):1437-1446.

Zhang YF, et al. Dose-related effects of radial extracorporeal shock wave therapy for knee osteoarthritis: A randomized controlled trial. J Rehabil Med 2021 Jan 13;53(1):jrm00144.

Zheng C, et al. Effectiveness of extracorporeal shock wave therapy in patients with tennis elbow: A meta-analysis of randomized controlled trials. Medicine (Baltimore) 2020 Jul 24;99(30):e21189.

Zhong Z, et al. A randomized controlled trial on the effects of low-dose extracorporeal shockwave therapy in patients with knee osteoarthritis. Arch Phys Med Rehabil 2019 Sep;100(9):1695-1702.

*Zimmermann R, et al. Extracorporeal shock wave therapy for the treatment of chronic pelvic pain syndrome in males: a randomized, double-blind, placebo-controlled study. Eur Urol 2009 Sep;56(3):418-24.

*Key Article

KEY WORDS

Lithotripsy, orthotripsy, Ossatron, extracorporeal pulse activation therapy (EPAT), extracorporeal acoustic wave therapy, pulsed acoustic cellular expression (PACE) therapy.

CMS COVERAGE FOR MEDICARE PRODUCT MEMBERS

Based on our review, extracorporeal shock wave therapy for musculoskeletal conditions is not addressed in National coverage determinations or policies.

There is currently a Local Coverage Determination (LCD) L38775 Extracorporeal Shock Wave Therapy (ESWT) for musculoskeletal conditions. Please refer to the following LCD website for Medicare Members

<https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdId=38775&ver=3> accessed 02/01/24.